

Table S1. Demographic characteristics of pediatric patients.

Age group	Number of patients (Male/Female)	Percentage (%)
Neonate (<28 days)	64 (42/22)	40.0
Young infant (28–90 days)	12 (5/7)	7.5
Infant (3–12 months)	8 (3/5)	5.0
Child (1–5 years)	34 (19/15)	21.3
Child (6–12 years)	41 (31/10)	25.6
Adolescent (≥ 13 years)	1 (1/0)	0.6
Total	160 (101/59)	100
Age (days) Median (Q1–Q3)	228 days (9.5–2,190)	

Table S2. Zone diameters and antimicrobial resistance rates of blood culture.

Species (isolates nos)	Antimicrobial	Amikacin	Colistin	Gentamicin	Meropenem	Tigecycline			
	Break point (susceptible/resistant, mm)	$\geq 17, \leq 14^a$	n.d.	$\geq 15, \leq 12$	$\geq 18, \leq 14$	n.d.			
<i>A. baumannii</i> (n = 11)	Mean ZD $\pm$ SD (mm)	16.5 ± 7.2	11 ± 2.8	14 ± 6.3	16.9 ± 9.0	22.7 ± 2.8			
	ZD range (mm)	6 to 24	7 to 15	6 to 20	6 to 26	17 to 26			
	Percentage of drug-resistant isolates (%)	36.4	n.d.	45.5	36.4	n.d.			
		Ampicillin	Cefepime	Cefotaxime	Ceftazidime	Ciprofloxacin	Colistin	Co-trimoxazole	Meropenem
	Break point (mm)	$\geq 17, \leq 13$	$\geq 25, \leq 18$	$\geq 18, \leq 14$	$\geq 21, \leq 17$	$\geq 26, \leq 21$	n.d.	n.d.	$\geq 23, \leq 19$
<i>E. coli</i> (n = 13)	Mean ZD $\pm$ SD (mm)	7.4 ± 5.0	15.8 ± 8.3	11.3 ± 8.8	12.9 ± 8.1	12.3 ± 10.2	11.8 ± 2.0	11.1 ± 9.7	21.9 ± 9.1
	ZD range (mm)	6 to 24	6 to 30	6 to 34	6 to 27	6 to 34	6 to 14	6 to 30	6 to 30
	Percentage of drug-resistant isolates (%)	92.3	69.2	92.3	69.2	76.9	n.d.	76.9	30.8
		Cefepime	Cefotaxime	Ceftazidime	Ciprofloxacin	Colistin	Co-trimoxazole	Meropenem	
	Break point (mm)	$\geq 25, \leq 18$	$\geq 18, \leq 14$	$\geq 21, \leq 17$	$\geq 26, \leq 21$	n.d.	n.d.	$\geq 23, \leq 19$	
<i>K. pneumoniae</i> (n = 85)	Mean ZD $\pm$ SD (mm)	11.2 ± 6.1	7.8 ± 5.4	8.5 ± 5.2	11.7 ± 7.2	13.1 ± 1.0	10.0 ± 6.7	14.1 ± 7.6	
	ZD range (mm)	6 to 31	6 to 31	6 to 28	6 to 28	8 to 15	6 to 25	6 to 28	
	Percentage of drug-resistant isolates (%)	91.8	93	88.5	84.1	n.d.	67.8	67.0	
		Cefoxitin							
	Break point (mm)	$\geq 22, \leq 21$							
<i>S. aureus</i> (n = 26)	Mean ZD $\pm$ SD (mm)	22.6 ± 5.2							
	ZD range (mm)	13 to 28							
	Percentage of drug-resistant isolates (%)	30.8							
		Cefotaxime	Ceftazidime	Ciprofloxacin	Meropenem				
	Break point (mm)	$\geq 26, \leq 22$	$\geq 22, \leq 19$	$\geq 31, \leq 20$	$\geq 23, \leq 19$				
<i>S. Typhi</i> (n = 25)	Mean ZD $\pm$ SD (mm)	31.7 ± 4.4	29.4 ± 3.8	7.7 ± 3.4	32.4 ± 3.4				
	ZD range (mm)	25 to 40	23 to 37	6 to 18	27 to 40				
	Percentage of drug-resistant isolates (%)	0	0	96.0	0				

MIC: minimum inhibitory concentration; n.d.: not determined; ZD: zone diameter.

^aBreakpoints for microbial resistance were determined following the guidelines of Clinical and Laboratory Standards Institute for all antimicrobial agents except for ceftazidime in *S. Typhi*, for which European Society of Clinical Microbiology and Infectious Diseases was used.^bCotrimoxazole: Trimethoprim:sulfamethoxazole in the ratio 1:5.